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Autoantibody production and autoantibody-mediated inflammation are hallmarks of 
a number of autoimmune diseases. The K/BxN serum-transfer arthritis is one of the 
most widely used models of the effector phase of autoantibody-induced pathology. 
Several hematopoietic lineages including neutrophils, platelets, and mast cells have 
been proposed to contribute to inflammation and tissue damage in this model. We have 
previously shown that the Syk tyrosine kinase is critically involved in the development in 
K/BxN serum-transfer arthritis and bone marrow chimeric experiments indicated that 
Syk is likely involved in one or more hematopoietic lineages during the disease course. 
The aim of the present study was to further define the lineage(s) in which Syk expression 
is required for autoantibody-induced arthritis. To this end, K/BxN serum-transfer arthritis 
was tested in conditional mutant mice in which Syk was deleted in a lineage-specific 
manner from neutrophils, platelets, or mast cells. Combination of the MRP8-Cre, PF4-
Cre, or Mcpt5-Cre transgene with floxed Syk alleles allowed efficient and selective 
deletion of Syk from neutrophils, platelets, or mast cells, respectively. This has also been 
confirmed by defective Syk-dependent in  vitro functional responses of the respective 
cell types. In vivo studies revealed nearly complete defect of the development of K/BxN 
serum-transfer arthritis upon neutrophil-specific deletion of Syk. By contrast, Syk dele-
tion from platelets or mast cells did not affect the development of K/BxN serum-transfer 
arthritis. Our results indicate that autoantibody-induced arthritis requires Syk expression 
in neutrophils, whereas, contrary to prior assumptions, Syk expression in platelets or 
mast cells is dispensable for disease development in this model.
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inTrODUcTiOn
A number of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, 
small vessel vasculitis, or pemphigoid diseases, are characterized by production of autoantibod-
ies against various autoantigens of the mammalian body (1). Those autoantibodies are thought to 
contribute to the autoimmune disease pathogenesis, either directly by engagement of their target 
autoantigens (activating or function-blocking autoantibodies), or by triggering an inflammatory 
reaction and concomitant tissue damage caused by the infiltrating inflammatory cells.
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The K/BxN serum-transfer arthritis is one of the most widely 
used mouse model of autoantibody-induced tissue damage. This 
model is initiated by systemic injection of serum from so-called 
K/BxN mice in which the expression of a specific T-cell-receptor 
transgene on an autoimmunity-prone genetic background leads 
to the generation of high titers of autoantibodies against the 
ubiquitously expressed glucose 6-phosphate isomerase enzyme 
(2–5). Transferring those autoantibodies with the K/BxN serum 
to naive animals triggers robust inflammation of the distal joints 
and of other tissues. K/BxN serum-transfer arthritis is triggered 
by immune complex (IC) deposition and concomitant activation 
of Fcγ-receptors (5). A number of hematopoietic lineages are 
thought to be involved in the development of K/BxN serum-
transfer arthritis. The role of neutrophils is indicated by the fact 
that antibody-mediated depletion (6) or genetic deletion (7, 8) 
of neutrophils prevents arthritis development in this model. 
Arthritis development was also reduced in mast cell-deficient 
KitW/W-v mice (9) suggesting an important role of mast cells. 
In addition, platelets were proposed to be required for the devel-
opment of K/BxN serum-transfer arthritis by releasing platelet-
derived microparticles upon collagen-induced activation in the 
synovial tissue (10).
Syk is a nonreceptor tyrosine kinase primarily expressed in 
cells of the hematopoietic lineage (11). It mediates signaling by 
a number of cell surface receptors including B-cell-receptors 
(12, 13), Fcγ- and Fcε-receptors (14–18), β2 and β3 integrins 
(19–21), C-type lectins (11, 22), and other receptors coupled 
to immunoreceptor tyrosine-based activation motifs (ITAMs) 
(11, 23). Given its role in various hematopoietic lineages and 
signaling downstream of diverse cell surface receptors, Syk is 
indispensable for a number of in vivo processes including B-cell 
development (12, 13), various inflammatory disease processes 
(17, 24, 25), antifungal immunity (26), or lymph vessel develop-
ment (27). Based on its central role in the immune system, Syk 
has been proposed as a therapeutic target in various autoimmune 
and inflammatory diseases (11, 28).
We have previously shown that Syk is critically involved 
in arthritis development in the autoantibody-induced K/BxN 
serum transfer model (25). Our additional studies indicated 
that Syk is involved in a pathway downstream of Fc-receptors 
and Src-family kinases (29) and activates further downstream 
processes through PLCγ2 (30) and CARD9 (31). However, it 
is at present incompletely understood in which lineage(s) Syk 
needs to be expressed for arthritis development in this model. 
Bone marrow chimeric experiments suggested the role for 
Syk in one or more hematopoietic lineages (25). Several lines 
of evidence suggest an important role for Syk in neutrophils 
(19, 31, 32). An important role for GpVI, an ITAM-coupled 
collagen receptor on platelets, for the development of K/BxN 
serum-transfer arthritis (10) suggested a role for Syk in platelets 
for disease development in this model (33). Finally, the proposed 
role of mast cells (9, 34) and the critical role for Syk in mast cell 
activation (14, 18) raised the possibility that Syk expression in 
mast cells contributes to development of K/BxN serum-transfer 
arthritis.
The above studies prompted us to perform lineage-specific 
deletion of Syk from neutrophils, platelets, and mast cells, and 
to test the effect of those mutations on the development of 
autoantibody-induced arthritis in the K/BxN serum-transfer 
model. Our results indicate an important role for Syk expres-
sion in neutrophils whereas, contrary to our expectations, Syk 
expression in platelets or mast cells appears to be dispensable for 
arthritis development in this model.
MaTerials anD MeThODs
animals
Mice carrying a deleted Syk allele (Syktm1Tyb, referred to as 
Syk−) (12) were kept in heterozygous form and used to obtain 
Syk−/− and control fetuses for fetal liver transplantation (19, 25). 
Lineage-specific deletion of Syk was achieved by crossing MRP8-
Cre (35), PF4-Cre (36), or Mcpt5-Cre transgenic mice (37) with 
animals carrying a floxed Syk allele (Syktm1.2Tara, referred to as 
Sykflox) (38) to obtain MRP8-Cre+Sykflox/flox, PF4-Cre+Sykflox/flox, 
and Mcpt5-Cre+Sykflox/flox mice, referred to as SykΔPMN, SykΔPLT, 
and SykΔMC animals, respectively. Mice carrying the KRN T-cell-
receptor transgene (2) were maintained in heterozygous form by 
mating with C57BL/6 mice. All transgenic mice were backcrossed 
to the C57BL/6 genetic background for at least six generations. 
Genotyping was performed by allele-specific PCR.
Wild type (WT) control C57BL/6 mice were purchased from 
Charles River or the Hungarian National Institute of Oncology 
(Budapest, Hungary). NOD mice, as well as a congenic strain 
carrying the CD45.1 allele on the C57BL/6 genetic background 
(B6.SJL-Ptprca) were purchased from the Jackson Laboratory.
Mice were kept in individually sterile ventilated cages (Tecniplast) 
in a conventional facility. All animal experiments were approved 
by the Animal Experimentation Review Board of the Semmelweis 
University.
Bone marrow chimeras were generated by intravenous injection 
of unfractionated bone marrow or fetal liver cells into recipients 
carrying the CD45.1 allele on the C57BL/6 genetic background, 
which were lethally irradiated before by 11 Gy from a 137Cs source 
using a Gamma-Service Medical (Leipzig, Germany) D1 irradia-
tor. 4 weeks after transplantation, peripheral blood samples were 
stained for Ly6G and CD45.2 (Clones 1A8 and 104, respectively; 
both from BD Biosciences) and analyzed by a BD Biosciences 
FACSCalibur flow cytometer as previously described (see Figure 
S1A in Supplementary Material) (29).
K/Bxn serum-Transfer arthritis
Mice carrying the KRN T-cell receptor transgene on the C57BL/6 
genetic background were mated with NOD mice to obtain 
transgene-positive (arthritic) K/BxN and transgene-negative 
(non-arthritic) BxN mice (2, 30). The presence of the transgene 
was determined by allele-specific PCR and confirmed by pheno-
typic assessment. Blood was taken by retroorbital bleeding and 
sera from arthritic and control mice were pooled separately.
Arthritis was induced by a single intraperitoneal injection 
of 300 μl K/BxN (arthritic) or BxN (control) serum into intact 
mice or bone marrow chimeras, followed by daily assessment 
of arthritis severity for 2 weeks as described (30, 31, 39). Visible 
clinical signs were scored on a 0–10 scale by two investigators 
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blinded for the origin and treatment of the mice. Ankle thickness 
was measured by a spring-loaded caliper (Kroeplin).
isolation and activation of neutrophils, 
Platelets, and Mast cells
Mouse neutrophils were isolated from the bone marrow of the 
femurs and tibias of intact mice or chimeras by hypotonic lysis 
followed by Percoll (GE Healthcare) gradient centrifugation 
using sterile and endotoxin-free reagents as described (18, 31, 39). 
Cells were kept at room temperature in Ca2+- and Mg2+-free 
medium until use and prewarmed to 37°C prior to activation. 
Neutrophil assays were performed at 37°C in HBSS supplemented 
with 20  mM HEPES, pH 7.4. Adhesion-dependent superoxide 
release by neutrophils was followed by a cytochrome c reduction 
test from 100 µl aliquots of 4 × 106/ml cells plated on fibrinogen 
(Calbiochem) coated surfaces in the presence of 50 ng/ml murine 
TNF-α (PeproTech) as described (39).
Platelets were isolated from peripheral blood by mild centrifu-
gation in the presence of heparin. For an in vitro aggregation assay 
(40), platelets were divided into two groups, one labeled with an 
anti-CD9-PE (Clone EM-04; Abcam) and the other one with 
an anti-CD9-APC (Clone eBioKMC8; eBioscience) antibody. 
The two differently labeled groups were mixed in equal volumes 
and were activated by 50 ng/ml Convulxin (Enzo Life Sciences) 
at 37°C while shaking at 700  rpm for 5 min. The reaction was 
stopped by BD FACS Lysing Solution (BD Biosciences). The 
samples were analyzed by flow cytometry, where platelets were 
identified according to their forward and side scatter characteris-
tics. Aggregation was determined as the percentage of CD9-PE/
CD9-APC double positive events (40).
Mast cells were cultured from the bone marrow in the 
presence of 5 ng/ml murine IL-3 and 20 ng/ml stem cell factor 
(both from PeproTech). The purity of the cultures was tested 
by an anti-FcεR antibody (Clone MAR-1; eBioscience) by flow 
cytometry. For in vitro activation, mast cells were first incubated 
with an anti-dinitrophenyl (DNP) IgE antibody (Clone SPE-7) 
at a final concentration of 0.5 µg/ml overnight at 37°C on fetal 
bovine serum (FBS)-coated plates, followed by the crosslink-
ing of Fcε receptors by the addition of 100 ng/ml DNP-human 
serum albumin to the cell suspensions (both reagents from 
Sigma-Aldrich). After 30 min, the cells were washed and mast 
cells were kept in Dulbecco’s Modified Eagle’s Medium (DMEM; 
Sigma-Aldrich) overnight at 37°C on FBS-coated plates. The 
release of the inflammatory mediator MIP-1α was tested from 
the cell-free supernatants by a commercial ELISA kit (R&D 
Systems) according to the manufacturer’s instructions. The 
absence of Syk did not have a major effect on neutrophil, platelet, 
or mast cell development and numbers (data not shown).
Biochemical studies
For analysis of protein contents, neutrophils, platelets, and mast 
cells were lysed in 100 mM NaCl, 30 mM Na-HEPES (pH 7.4), 
20  mM NaF, 1  mM Na-EGTA, 1% Triton X-100, 1  mM ben-
zamidine, freshly supplemented with 0.1 U/ml Aprotinin, 1:100 
Mammalian Protease Inhibitor Cocktail, 1:100 Phosphatase 
Inhibitor Cocktail 2, 1 mM PMSF, and 1 mM Na3VO4 (all from 
Sigma-Aldrich). After removal of insoluble material, lysates were 
boiled in sample buffer. Whole cell lysates were run on SDS-PAGE 
and immunoblotted using antibodies against Syk (Clone N19; 
Santa Cruz) or β-actin (Clone AC-74; Sigma-Aldrich) followed 
by peroxidase-labeled secondary antibodies (GE Healthcare). The 
signal was then developed using the ECL system (GE Healthcare) 
and exposed to X-ray film.
Presentation of the Data and statistical 
analysis
Experiments were performed the indicated number of times. 
Quantitative graphs and kinetic curves show mean and SEM from 
all independent in vitro experiments or from all individual mice 
from the indicated number of experiments. Statistical analyses 
were carried out by the STATISTICA software using two-way 
(factorial) ANOVA, with treatment and genotype being the two 
independent variables. In case of kinetic assays, area under the 
curve was used for statistical analysis. P values below 0.05 were 
considered statistically significant.
resUlTs
K/Bxn serum-Transfer arthritis in syk−/− 
Bone Marrow chimeras
To test the role of Syk within hematopoietic lineage cells, we 
generated bone marrow chimeric mice by transplanting Syk−/− or 
WT control fetal liver cells into lethally irradiated recipients. 
As shown in Figure 1A, injection of arthritogenic K/BxN serum 
into WT control chimeras triggered robust inflammation of the 
ankle joints whereas no such response could be observed in Syk−/− 
bone marrow chimeras which carry Syk-deficient hematopoietic 
tissues. Quantitative kinetic analysis of the clinical scoring of 
arthritis (Figure 1B) or the ankle thickness (Figure 1C) revealed 
that Syk−/− bone marrow chimeras were completely protected 
from arthritis development in this model (p =  3  ×  10−6 and 
p = 1.3 × 10−3, respectively). Those results confirmed our prior 
studies showing critical role for Syk in the hematopoietic com-
partment in K/BxN serum-transfer arthritis (25).
syk is expressed in neutrophils, Platelets, 
and Mast cells
Prior studies suggested a role for neutrophils, platelets, and mast 
cells in K/BxN serum-transfer arthritis (6–10, 34), as well as the 
functional role for Syk in those cells (14, 16, 18–20). To confirm 
the presence of Syk in those lineages and its deletion from Syk−/− 
cells, we tested the expression of Syk in primary neutrophils 
and platelets, or bone marrow-derived mast cells, from WT and 
Syk−/− bone marrow chimeras. As shown in Figure 1D, Syk was 
present in all three cell types derived from WT but not Syk−/− 
bone marrow chimeras (see the entire blots in Figures S1B–D in 
Supplementary Material).
efficacy and specificity of syk Deletion 
From neutrophils, Platelets, and Mast cells
To test the role of Syk in a linage-specific manner, we turned to Cre-
lox-mediated lineage-specific conditional deletion of Syk. To this 
FigUre 2 | The efficacy and specificity of lineage-specific Syk deletion from 
different cell types. The efficacy and specificity of lineage-specific deletion 
was tested by immunoblotting of whole cell lysates of neutrophils (a), 
platelets (B), and mast cells (c) derived from wild type (WT), SykΔPMN, SykΔPLT, 
or SykΔMC mice or from Syk−/− bone marrow chimeras. Blots are 
representative of three independent experiments.
FigUre 1 | Autoantibody-induced arthritis in Syk-deficient bone marrow chimeras. Wild type (WT) and Syk−/− bone marrow chimeras were injected with BxN 
(Control) or K/BxN (Arthritic) serum intraperitonally on day 0. Arthritis development was followed by photographing on day 7 (a), clinical scoring of the hind limbs (B), 
and ankle thickness measurement (c). Panel (D) shows the absence of the Syk tyrosine kinase from whole cell lysates of Syk−/− neutrophils, platelets, and mast 
cells. Photos are representative of, and quantitative data show mean and SEM from, four control and four to five arthritic serum-treated individual mice per group 
from two independent experiments. Western blot images are representative of two to three independent experiments. See the text for actual p values.
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end, we generated mice carrying the Sykflox/flox mutation along with 
a neutrophil-specific MRP8-Cre (SykΔPMN), the platelet-specific 
PF4-Cre (SykΔPLT), or the mast cell-specific Mcpt5-Cre (SykΔMC) 
transgenes. We then isolated neutrophils or platelets, and cultured 
bone marrow-derived mast cells, from those animals. As shown 
in Figure 2A, Syk expression was strongly reduced in SykΔPMN, but 
was not affected in SykΔPLT or SykΔMC neutrophils. Similarly, Syk 
was absent from SykΔPLT but not from SykΔPMN or SykΔMC platelets 
(Figure 2B). Finally, Syk expression was abrogated in SykΔMC but 
not in SykΔPMN or SykΔPLT mast cells (Figure 2C; see the entire blots 
in Figure S2 in Supplementary Material). Those results confirm 
both the efficacy and the specificity of the SykΔPMN, SykΔPLT, and 
SykΔMC mutations.
lineage-specific Deletion of syk 
abrogates Functional responses of 
neutrophils, Platelets, and Mast cells
To test the functional efficacy of lineage-specific Syk deletion, we 
also tested supposedly Syk-dependent functional responses of 
neutrophils, platelets, and mast cells. Superoxide release of neu-
trophils plated on a fibrinogen surface in the presence of a soluble 
TNF stimulus is mediated by β2 integrins in a supposedly Syk-
dependent manner (19). As shown in Figure 3A, this response 
was nearly completely blocked in neutrophils from SykΔPMN 
animals (p =  0.02). Convulxin is a snake venom toxin activat-
ing the Fc-receptor-related collagen receptor GpVI on platelets 
in a Syk-dependent manner (40, 41). As shown in Figure  3B, 
convulxin induced aggregation of WT but not SykΔPLT platelets 
(p = 0.03). Crosslinking of IgE bound to the surface of mast cells 
triggers release of various proinflammatory mediators through 
Fcε-receptors in a Syk-dependent manner (14). As shown in 
Figure 3C, MIP-1α release induced by IgE crosslinking of mast 
cells was abrogated by the SykΔMC mutation (p = 1.3 × 10−4). Those 
FigUre 3 | Syk is indispensable for immunoreceptor tyrosine-based activation motif-mediated in vitro cellular responses of neutrophils, platelets, and mast cells.  
(a) Wild type (WT) or SykΔPMN neutrophils were plated on fibrinogen-coated surfaces in the presence of TNF-α and their superoxide release was measured by a 
cytochrome c reduction test. Control data points were subtracted. (B) WT or SykΔPLT platelets were isolated from peripheral blood, labeled by two different 
fluorochrome-conjugated CD9 antibodies and were activated by convulxin (CVX) for 5 min. Aggregation was measured as the percentage of CD9-PE/CD9-APC 
double positive events. (c) WT or SykΔMC bone marrow-derived mast cells were incubated with anti-DNP IgE antibodies followed by an Fcε receptor crosslinking 
step with DNP-HSA. MIP-1α levels were determined from the cell-free supernatant by an ELISA assay. Kinetic curves and graphs represent mean and SEM from 
three (a,c) or six (B) samples from three (a) or two (B,c) independent experiments. See the text for actual p values. DNP, dinitrophenyl; HSA, human serum 
albumin, IC, immune complex.
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results indicate that lineage-specific deletion of Syk from neu-
trophils, platelets, or mast cells leads to the expected functional 
consequences in those cells.
neutrophil-specific Deletion of syk 
abrogates autoantibody-induced arthritis
We next tested the consequence of neutrophil-specific deletion 
of Syk on the development of K/BxN serum-transfer arthritis. 
As shown in Figure  4A, arthritogenic K/BxN serum triggered 
visible arthritis development in WT animals. However, no signs 
of arthritis could be observed in SykΔPMN animals (Figure 4A). 
Quantitative kinetic analysis revealed that SykΔPMN mice were 
nearly completely protected from development of clinical signs of 
arthritis (Figure 4B; p = 1.5 × 10−5) and arthritis-induced ankle 
swelling (Figure  4C; p =  1.7 ×  10−3). Similar results could be 
observed when testing a larger cohort of bone marrow chimeras 
generated by transplanting WT or SykΔPMN bone marrow cells into 
lethally irradiated WT recipients (Figures 4D,E; p = 6.2 × 10−7 
and p = 3.2 × 10−6, respectively). Those results indicate a critical 
role for Syk expression within neutrophils for the development of 
autoantibody-induced arthritis in vivo.
normal arthritis Development Upon 
Platelet-specific Deletion of syk
Boilard et al. previously showed that genetic deletion of the Syk-
coupled GpVI collagen receptor of platelets strongly reduced 
arthritis development in the K/BxN serum-transfer model (10), 
suggesting an important role for Syk expression in platelets in 
this model (33). To test this hypothesis experimentally, we tested 
K/BxN serum-transfer arthritis in SykΔPLT mice in which Syk was 
deleted in a platelet-specific manner. Contrary to our expecta-
tions, platelet-specific Syk deletion did not affect the development 
of visual signs of arthritis in our model (Figure 5A). Quantitative 
kinetic analysis did not reveal any effect of the SykΔPLT mutation 
on the clinical appearance (Figure 5B; p = 0.51) or on the ankle 
thickness increase (Figure 5C; p = 0.76) either. Similar results were 
obtained when using bone marrow chimeras generated by trans-
planting WT or SykΔPLT bone marrow cells into lethally irradiated 
WT recipients (Figures 5D,E; p = 0.49 and p = 0.9, respectively). 
Those results, together with the lack of Syk (Figure 2B) and the 
defective Syk-dependent functional activation (Figure  3B) of 
SykΔPLT platelets indicate that Syk expression in platelets is not 
required for the development of K/BxN serum-transfer arthritis.
Mast cell-specific syk Deletion Does not 
affect autoantibody-induced arthritis
Mast cells are one of the major targets of Syk function (14, 18) 
and they have also been proposed to participate in the develop-
ment of K/BxN serum-transfer arthritis (9, 34). Therefore, we 
hypothesized that Syk expression in mast cells may be required 
for arthritis development in this model. To this end, we tested the 
development of K/BxN serum-transfer arthritis in SykΔMC mice. 
As shown in Figure 6A, the SykΔMC mutation did not affect the 
development of visible signs of arthritis in our model. Quantitative 
kinetic analysis did not reveal any inhibition of arthritis develop-
ment either when scoring clinical signs of arthritis (Figure 6B; 
p = 0.38) or when measuring arthritis-induced increase of ankle 
thickness (Figure 6C; p =  0.37). By contrast, there was even a 
tendency of earlier arthritis development in the SykΔMC animals 
(Figures 6B,C), raising the possibility of a negative role of Syk 
expressed in mast cells. Because of the radioresistance of mast 
cells, no bone marrow chimeras have been generated using SykΔMC 
mice. The lack of inhibition of arthritis in SykΔMC animals, together 
with the dramatic reduction of Syk expression (Figure 2C) and 
Syk-mediated functional responses (Figure 3C) in SykΔMC mast 
cells indicates that Syk expression within mast cells is dispensable 
for arthritis development in the K/BxN serum-transfer model.
DiscUssiOn
The Syk tyrosine kinase is critically involved in various inflamma-
tory disease processes including the development of autoantibody-
induced arthritis and dermatitis models (11, 17, 25). Given the 
wide expression of Syk in practically all hematopoietic lineages 
(11), understanding Syk function in a lineage-specific manner 
is of particular importance. Our results presented in this work 
indicate that of the three most prominent Syk-expressing lineages 
supposedly involved in the development of autoantibody-induced 
FigUre 4 | Neutrophil-specific Syk deletion attenuates experimental arthritis. Wild type (WT) and SykΔPMN intact animals (a–c) or bone marrow chimeras (D,e) were 
injected with BxN (Control) or K/BxN (Arthritic) serum intraperitonally on day 0. Arthritis development was followed by photographing (a), clinical scoring of the hind 
limbs (B,D), and ankle thickness measurement (c,e). Quantitative data show mean and SEM from three control and five to six arthritic serum-treated individual mice 
per group from three independent experiments (B,c) or from five control and five to seven arthritic serum-treated mice per group from three independent 
experiments (D,e). See the text for actual p values.
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arthritis, Syk expression in neutrophils is critical, whereas that 
in platelets or mast cells is dispensable, for the development of 
K/BxN serum-transfer arthritis.
We and others have shown that Syk plays a critical role in 
various functional responses of neutrophils (16, 17, 19, 42, 43) 
without affecting neutrophil development (17, 19). Neutrophils 
have also been shown to be critical for the development of 
autoantibody-induced arthritis (6–8), likely at least in part 
through IgG IC-mediated activation of Fcγ-receptors expressed 
on the neutrophil cell surface (29), as well as by yet incompletely 
understood neutrophil-mediated initial vascular changes (8). 
Based on those studies, we hypothesized that Syk expression 
within neutrophils is critical for autoantibody-induced arthritis 
development. Our results confirmed that hypothesis, and they 
were also in line with prior studies from other groups (32) and 
our own analysis of neutrophil-specific deletion of the CARD9 
adapter protein, a supposedly downstream effector of Syk (31). 
Though it is at present incompletely understood how Syk within 
neutrophils participates in autoantibody-induced arthritis 
development, our prior studies showing defective release of 
proinflammatory mediators by Syk-deficient neutrophils despite 
normal intrinsic migratory capacity of the cells (17, 19, 31) sug-
gest that Syk, similar to Src-family kinases (29), participates in the 
amplification of neutrophil recruitment by neutrophil-derived 
proinflammatory mediators (44).
In contrast to our neutrophil-specific deletion studies, our 
platelet-specific deletion experiments did not support our hypo-
thesis based on literature data. Though Syk is not required for 
platelet development (20), it plays a critical role in various platelet 
functions (11) including αIIbβ3 integrin-dependent platelet 
spreading (20), responses mediated by the hemITAM-coupled 
C-type lectin CLEC-2 (45), as well as signaling downstream of 
GpVI, an ITAM-coupled collagen-receptor of platelets (40, 41). 
GpVI is closely related to Fcα-receptors and it is directly associ-
ated with, and supposedly signals through, the ITAM-containing 
Fc-receptor γ-chain (FcRγ) (40, 41, 46–49). Platelets and, specifi-
cally, GpVI has been shown to play a critical role in the develop-
ment of K/BxN serum-transfer arthritis (10), suggesting that Syk 
expression downstream of platelet GpVI is critically involved in 
arthritis development in this model (33). Our results of normal 
arthritis development upon platelet-specific deletion of Syk 
(Figure 5) despite practically complete lack of Syk from platelets 
FigUre 5 | Platelet-specific Syk deletion has no effect on autoantibody-induced arthritis. Wild type (WT) and SykΔPLT intact animals (a–c) or bone marrow chimeras 
(D,e) were injected with BxN (Control) or K/BxN (Arthritic) serum intraperitonally on day 0. Arthritis development was followed by photographing (a), clinical scoring 
of the hind limbs (B,D), and ankle thickness measurement (c,e). Quantitative data show mean and SEM from three control and five arthritic serum-treated individual 
mice per group from three independent experiments (B,c) or from six control and eight to nine arthritic serum-treated mice per group from three independent 
experiments (D,e). See the text for actual p values.
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(Figure  2) and completely defective GpVI-mediated in  vitro 
platelet function (Figure 3) argues against that hypothesis. There 
are several possible explanations for those findings. Though GpVI 
is associated with the ITAM-containing FcRγ adapter, it may be 
able to bypass the ITAM-Syk pathway under certain conditions, 
using FcRγ as a chaperone required for cell surface expression 
but not as an ITAM-mediated signaling adaptor. Platelets have 
also been proposed to interact with fibroblast-like synoviocytes 
in a COX-1-dependent manner which is independent of platelet 
GpVI or FcRγ expression (50). This pathway may be able to com-
pensate for the defective GpVI–FcRγ–Syk pathway upon platelet-
specific Syk deletion. We also cannot exclude the possibility that 
GpVI needs to be expressed in a non-platelet lineage to support 
autoantibody-induced arthritis in mice. Finally, technical details 
such as a role for the small remaining Syk expression after Cre-
mediated Syk deletion, or different experimental conditions may 
also account for the different conclusions drawn from our study 
and from those proposing a critical role for the platelet GpVI–
FcRγ–Syk pathway in autoantibody-induced arthritis (10, 33). 
It should also be mentioned that our study focused on visible signs 
of arthritis and therefore we cannot exclude the possibility that 
Syk expression in platelets modulates the inflammation process 
by a mechanism not clearly visible by macroscopic inspection.
In the third part of our study, we tested the role of Syk in mast 
cells during autoantibody-induced arthritis. Syk has been shown 
to play a critical role in mast cell function without affecting mast 
cell survival (14, 18) and mast cells were proposed to be impor-
tant players in autoantibody-induced arthritis development (9). 
Therefore, we hypothesized that Syk expression in mast cells may 
play a role in the development of K/BxN serum-transfer arthritis. 
Our results showing normal arthritis development in that model 
upon mast cell-specific Syk deletion (Figure 6) despite strongly 
reduced Syk expression (Figure  2) and defective Syk-mediated 
functional responses (Figure 3) in mast cells argue against that 
possibility. There are several possible explanations for those 
findings. Since the mechanism of how mast cells contribute to 
IgG autoantibody-induced disease pathogenesis is incompletely 
understood, it is possible that mast cells use a Syk-independent 
signal transduction pathway during K/BxN serum-transfer 
arthritis (e.g., when mast cells are not directly activated by the 
autoantibody-containing ICs, but rather indirectly through 
Syk-independent chemokine, cytokine, or PRR pathways). It 
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should also be mentioned that follow-up studies have questioned 
the critical role of mast cells in autoantibody-induced arthritis 
development (51, 52), pointing to difficulties of the interpretation 
of data obtained with different mast cell-deficient mouse strains. 
Indeed, our limited preliminary studies also suggested that the 
role of mast cells is highly dependent on the experimental condi-
tions used for triggering autoantibody-induced arthritis in mice 
(Z. Jakus and A. M., unpublished observations). Finally, given 
that our experiments focused on visible signs of inflammation, 
we cannot exclude the possibility that Syk expression in mast cells 
may modulate arthritis development or the overall inflammation 
process in a manner not clearly visible by macroscopic assessment.
Besides neutrophils, platelets, and mast cells, Syk is also 
expressed in other lineages possibly involved in arthritis develop-
ment. B-cells are one of the most prominent lineages requiring 
Syk function (12, 13). However, it is unlikely that Syk expressed in 
B-cells contributes to K/BxN serum-transfer arthritis since that 
model mimics the post-immunization effector phase of autoim-
mune arthritis and it develops normally even in the absence of 
B-cells in μMT-deficient or Rag-deficient mice (3). Macrophages 
have been proposed to be important players in the development 
of K/BxN serum-transfer arthritis (53). Unfortunately, currently 
available techniques do not allow the proper analysis of the 
in vivo relevance of Syk expression within macrophages because 
of the limited spectrum/specificity of the available macrophage-
specific Cre-expressing mouse strains (54). We have previously 
shown that Syk is critically involved in osteoclast development 
and function (23). Though understanding the role of Syk in 
arthritis-induced bone erosions would be of clear importance, 
this question is beyond the scope of the present study focusing 
on the inflammatory aspect of autoantibody-induced disease 
processes.
Taken together, our results provide understanding of the role 
of Syk in autoantibody-induced arthritis at the cellular lineage 
level. Our findings indicate a critical role for Syk expression in 
neutrophils, but refute prior assumptions for the role of Syk in 
platelets and argue against a role for Syk expression in mast cells. 
Those results will strongly contribute to the understanding of the 
pathomechanism of autoantibody-mediated disease processes at 
the cellular and molecular level.
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